首页> 中文期刊> 《临床心身疾病杂志》 >暴露反应阻止对5-羟色胺再摄取抑制剂抵抗强迫症患者疗效的影响

暴露反应阻止对5-羟色胺再摄取抑制剂抵抗强迫症患者疗效的影响

         

摘要

Objective To survey the influences of exposure‐response prevention (ERP) on efficacy of SS‐RI‐resistant obsessive‐compulsive disorder (OCD) .Methods ERP therapies were given to 36 SSRI‐resist‐ant OCD patients for 15 weeks .Efficacies were assessed with the Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS) and Symptom Checklist‐90 (SCL‐90) before and after treatment .Results At the end of 15 week treatment total effective rate of the patients was 72 .2% ,the total ,obsessional thoughts and compul‐sive behavior score of the Y‐BOCS as well as the total and each factor score of the SCL‐90 lowered more significantly compared with pretreatment (P<0 .01) .Conclusion ERP therapy is more effective in SSRI‐resistant OCD ,could notably improve patients’ mental symptoms ,and deserves clinical generalization and application .%目的:了解暴露反应阻止疗法对5‐羟色胺再摄取抑制剂治疗无效强迫症患者临床疗效的影响。方法对36例5‐羟色胺再摄取抑制剂治疗无效的强迫症患者予以暴露反应阻止疗法治疗,观察15周。于治疗前后采用 Yale‐Brow n强迫症状量表及症状自评量表评定临床疗效。结果治疗15周末,本组患者总有效率为72.2%,Yale‐Brow n强迫症状量表总分及强迫思维、强迫行为因子分和症状自评量表总均分及各因子分均较治疗前显著降低(P<0.01)。结论暴露反应阻止疗法对5‐羟色胺再摄取抑制剂治疗无效的强迫症患者临床疗效显著,且能显著改善患者的精神状况,值得临床推广应用。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号